

Enfuvirtide (ENF, T-20, Fuzeon)

For additional information see Drugs@FDA:

<http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm>

Formulations

Lyophilized powder for injection: 108-mg vial of ENF. Reconstitution with 1.1 mL sterile water will deliver 90 mg/mL.

Convenience kit: 60 single-use vials of ENF (90-mg strength), 60 vials of sterile water for injection, 60 reconstitution syringes (3 mL), 60 administration syringes (1 mL), alcohol wipes

Dosing Recommendations

Pediatric/adolescent dose (6–16 years of age):

Children <6 years of age:

ENF is not approved for use in children <6 years of age.

Children ≥6 years of age:

2 mg/kg (maximum dose, 90 mg [1 mL]) twice daily injected subcutaneously into the upper arm, anterior thigh, or abdomen.

Adolescent (>16 years of age)/adult dose:

90 mg (1 mL) twice daily injected subcutaneously into the upper arm, anterior thigh, or abdomen.

Selected Adverse Events

- Local injection site reactions.
- Increased rate of bacterial pneumonia (unclear association).
- Hypersensitivity reaction (HSR)—symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Rechallenge is not recommended.

Special Instructions

- Carefully instruct patient or caregiver in proper technique for drug reconstitution and administration of subcutaneous injections. ENF injection instructions are provided with convenience kits.
- After adding sterile water to vial of ENF, allow vial to stand until the powder goes completely into solution, which could take up to 45 minutes. Do not shake.
- Once reconstituted, inject ENF immediately or keep refrigerated in the original vial until use. Reconstituted ENF must be used within 24 hours.
- ENF must be given subcutaneously; severity of reactions increases if given intramuscularly.
- Give each injection of ENF at a site different from the preceding injection site; do not inject into moles, scar tissue, bruises, or the navel. Both the patient/caregiver and health care provider should carefully monitor for signs and symptoms of local infection or cellulitis.
- To minimize local reactions apply ice or heat after injection or gently massage injection site to better disperse the dose. There are reports

of injection-associated neuralgia and paresthesia if alternative delivery systems, such as needle-free injection devices, are used.

- Advise patient/caregiver of the possibility of an HSR; instruct them to discontinue treatment and seek immediate medical attention if the patient develops signs and symptoms consistent with an HSR.

Metabolism

- Catabolism to constituent amino acids.

Drug Interactions (See also the [Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents](#)):

- There are no known significant drug interactions with enfuvirtide.

Major Toxicities:

- *More common:* Almost all patients (87%–98%) experience local injection site reactions including pain and discomfort, induration, erythema, nodules and cysts, pruritis, and ecchymosis. Reactions are usually mild to moderate in severity but can be more severe. Average duration of local injection site reaction is 3–7 days, but was >7 days in 24% of patients.
- *Less common (more severe):* Increased rate of bacterial pneumonia (unclear association).
- *Rare:* HSRs in <1% of patients, including fever, nausea and vomiting, chills, rigors, hypotension, and elevated liver transaminases; immune-mediated reactions including primary immune complex reaction, respiratory distress, glomerulonephritis, and Guillain-Barre syndrome. Patients experiencing HSRs should seek immediate medical attention. Therapy should not be restarted in patients with signs and symptoms consistent with HSRs.
- *Pediatric specific:* Local site cellulitis requiring antimicrobial therapy (up to 11% of children in certain subgroups of patients in pediatric studies)¹.

Resistance: The International Antiviral Society-USA (IAS-USA) maintains a list of updated resistance mutations (see http://www.iasusa.org/resistance_mutations/index.html) and the Stanford University HIV Drug Resistance Database offers a discussion of each mutation (see <http://hivdb.stanford.edu/pages/GRIP/ENF.html>).

Pediatric Use:

Although enfuvirtide is Food and Drug Administration (FDA) approved for use in children, it is not commonly used because of its high cost, need for twice-daily subcutaneous injections, and high rate of injection site reactions. Use in deep salvage regimens² has also declined with the availability of integrase inhibitors and other entry inhibitors (e.g., maraviroc).

A single-dose pharmacokinetic (PK) evaluation study of enfuvirtide given subcutaneously to 14 HIV-infected children 4–12 years of age (PACTG 1005) identified that enfuvirtide 60 mg/m² of body surface area per dose resulted in a target trough concentration that approximated the “equivalent” of a 90-mg

dose delivered subcutaneously to an adult (1,000 ng/mL)³. In a second pediatric study of 25 children 5–16 years of age, a 2-mg/kg dose (maximum 90 mg) of enfuvirtide given twice daily, yielded drug concentrations similar to 60 mg/m² of body surface area dose independent of age group, body weight, body surface area, and sexual maturation⁴. The FDA-recommended dose of enfuvirtide for children 6–16 years of age is 2 mg/kg (maximum 90 mg) administered subcutaneously twice daily. Further data are needed for dosing in children <6 years of age.

The safety and antiretroviral (ARV) activity of twice-daily subcutaneous enfuvirtide administration at 60 mg/m² per dose plus optimized background therapy (OBT) was evaluated over 96 weeks in 14 children 4–12 years of age who had failed to achieve viral suppression on multiple prior ARV regimens (PACTG 1005). At 24 weeks 71% of the children had a >1.0 log reduction in viral load; 43% and 21% had HIV RNA levels suppressed to <400 copies/mL and <50 copies/mL, respectively⁵. However, only 36% of children maintained virologic suppression (>1.0 log decrease in HIV RNA) at Week 96. Most children had local injection site reactions⁶. Significant improvements in CD4 percentage and height z score were observed in children receiving enfuvirtide for 48 and 96 weeks.

T20-310, a Phase I/II study of enfuvirtide (2.0 mg/kg subcutaneously, maximum 90 mg, twice daily) plus OBT, enrolled 52 treatment-experienced children 3–16 years of age for 48 weeks. Only 64% of the children completed 48 weeks of therapy. The median decrease in HIV RNA was -1.17 log₁₀ copies/mL (n = 32) and median increase in CD4 count was 106 cells/mm³ (n = 25). At Week 8, treatment responses as measured by several plasma HIV RNA parameters were superior in younger children (<11 years of age) compared with adolescents. Median increases in CD4 count were 257 cells/mm³ in children and 84 cells/mm³ in adolescents. Local skin reactions were common in all age groups (87% of study participants). The observed differential responses between children and adolescents probably reflect unique challenges to adherence with the prescribed regimen¹.

An increased rate of bacterial pneumonia was observed in adults treated with enfuvirtide in some studies (FDA) but not in others⁷. Pediatric studies have lacked the statistical power to answer questions concerning enfuvirtide use and increased risk of pneumonia.

References

1. Wiznia A, Church J, Emmanuel P, et al. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. *Pediatr Infect Dis J*. 2007;26(9):799-805.
2. Feiterna-Sperling C, Walter H, Wahn V, et al. A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide. *Eur J Med Res*. 2009;14(1):44-46.
3. Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. *Pediatr Infect Dis J*. 2002;21(7):653-659.
4. Bellibas SE, Siddique Z, Dorr A, et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. *Pediatr Infect Dis J*. 2004;23(12):1137-1141.
5. Cunningham C, Church J, Hughes M, et al. Chronic subcutaneous T-20 (enfuvirtide) in HIV-infected children: 48 week outcome. 40th Annual Meeting of the Infectious Disease Society of America. October 24-27, 2002; Chicago, IL. Abstract 441.
6. Church JA, Hughes M, Chen J, et al. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. *Pediatr Infect Dis J*. 2004;23(8):713-718.
7. Kousignian I, Launay O, Mayaud C, et al. Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy? *J Antimicrob Chemother*. 2010;65(1):138-144.